Stryker shares fell 7.0% on 30 October 2026, the first full trading session after the medical-technology company cut its full-year guidance even as it reported double-digit growth in adjusted profit.

A quarter that grew but missed its own bar

Stryker's third-quarter net sales rose 7.7% to $6.5 billion, with organic growth also at 7.7%, driven by higher unit volumes across both its MedSurg and Neurotechnology and Orthopaedics segments. Reported operating margin was 15.9%, while adjusted operating margin reached 26.2%, up 60 basis points from a year earlier. Reported net earnings per diluted share fell 11.7% to $1.96, weighed down by a $293 million goodwill impairment and other one-off charges, but adjusted EPS, which strips those out, rose 10.3% to $3.52.

A move several times the stock's normal day

The fall was 3.6x Stryker's typical daily move of 2.0% over the past year, taking shares to $289.99 from a previous close of $311.75. It was also well beyond the session's broader market and sector moves: the S&P 500 fell 1.2% that day, and the median move among other covered health care equipment companies was −1.5%, pointing to a company-specific reaction rather than a sector-wide one. The last comparable decline in this direction came on 8 September 2026. Volume ran at only 0.6x the 30-day average, so the repricing happened without an unusual surge in shares changing hands.

Buybacks expanded the same day guidance was cut

The strongest alternative reading sits inside the same filing. Stryker repurchased $1.0 billion of its own stock in the third quarter, and in October 2026 its board approved a $3.0 billion increase to the existing buyback programme. Those are decisions the company made alongside the guidance cut, not a market reaction to it, and they do not on their own explain why the shares fell. But they show management continuing to return cash even as it lowered the sales outlook, a detail that sits uneasily with a reading of the quarter as an outright deterioration in the business.

What a −7.0% drop means for Stryker's value

The guidance cut is a growth signal, and growth is the input our model is most sensitive to. Our base case already assumes stage-one growth of 7.9%, close to the 7.7% organic growth Stryker just reported. If that stage-one growth runs 5 percentage points lower, model value falls 27.6%; if it runs 5 percentage points higher, model value rises 35.9%. A 1 percentage point increase in the discount rate would lower model value by −16.6%. Margin moves matter too, but less: each 1 percentage point of lower free-cash-flow margin lowers model value by −5.8%, while the margin actually improved over the past year, a move that would lift model value by 4.1% if it persists. Our base-case model value per share stands at $250.00. These are model values under stated assumptions, not a comparison with the share price.